Article Text

Download PDFPDF
994 Histopathological spectrum of ovarian masses – a retrospective study
  1. Sabuhi Qureshi,
  2. Sudha Kumari and
  3. Ritu Tripathi
  1. Kalyan Singh Super Specialty cancer institute, Lucknow, India


Introduction/Background Ovarian cancer is estimated to be the third most common gynaecological cancer globally following cervical & uterine cancers in females. The age adjusted incidence in India varies from 0.9 to 8.4 cases per 100,000 women. Advanced staged ovarian cancer has dismal prognosis with highest case fatality ratio amongst all gynaecological cancers contributing to 3.34% of all cancer deaths in India. The present study was planned to review the epidemiology, histomorphology and management of cases of Ovarian tumor attending the outpatient department of KSSSCI, Lucknow from 2020- 2023.

Methodology A retrospective analysis of cases of ovarian tumor attending outpatient department of KSSSCI, Lucknow.

Results 71 patients attended the hospital with ovarian tumors. The age range was 10- 79 years and 53.5% of patients were in 30–49 years of age. 18.5% were nulliparous whereas 52% were para one to para three. 20.3% had benign ovarian tumor. Of the malignant tumors (79.6%), maximum patients had Stage III at the time of presentation. Majority had high grade invasive & 3% had Borderline serous epithelial tumor. Of the malignant tumors, half were high grade serous carcinoma. The rest were mucinous (7%), Endometroid and clear cell 1.5% and 3% respectively. The germ cell tumors were 7% and there was one case each of granulosa cell tumor, mixed mullerian tumor and Krukenberg tumor (primary colon carcinoma). 63 patients underwent debulking surgery (69% had interval debulking and 31% had primary debulking).

Conclusion Malignant ovarian are commoner than non neoplastic lesions in premenopausal and post menopausal women as compared to adolescents. Epithelial ovarian cancers were the most common histological type, of which high grade serous carcinomas were most common. Significant number of patients presented at late stages requiring neo-adjuvant chemotherapy followed by cytoreductive surgery.

Disclosures None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.